岭南现代临床外科2016，Vol.16Issue(5)：553-556,4.DOI:10.3969/j.issn.1009-976X.2016.05.010
奥沙利铂或伊立替康联合氟尿嘧啶在KRAS突变型的晚期结直肠癌一线化疗中的疗效比较
Comparison of oxaliplatin-based and irinotecan-based regimen in the first-line treatment of KRAS mutation advanced colorectal cancer
摘要
Abstract
Objective Some researches found that KRAS mutation advanced colorectal cancer may predict sensitivity to oxaliplatin. This acticle enlarge more samples based on previous research. Objective to investigate which is the better regimen for KRAS mutation advanced colorectal cancer. Methods Between 2005 and 2016 , 112 advanced colorectal cancer patients with KRAS mutation were retrospectively analyzed. Of them 72 patients received first-line oxaliplatin-based chemotherapy while 40 patients received iriontecan-based chemotherapy. The primary endpoint was overall survival , the secondary endpoints were disease control rates and progression-free survival. Results Median overall survival was 24.9 months for oxaliplatin and 26.5 months for iriontecan (P=0.978), with DCR was 69.4% and 62.5%, respectively (x2=0.561,P=0.454). Median progression-free survival was 8.5 months for oxaliplatin and 8.5 months for iriontecan which had no statistical significance (P=0.412). Conclusion It was demonstrated that oxaliplatin-based chemotherapy and iriontecan-based chemotherapy in the first-line had similar efficacy in patients with KRAS mutation advanced colorectal cancer.关键词
KRAS突变/晚期结直肠癌/奥沙利铂/伊立替康/氟尿嘧啶Key words
KRAS mutation/Advanced colorectal cancer/Oxaliplatin/Irinotecan/Fluorouracil分类
医药卫生引用本文复制引用
叶炜芃,陈燕贤,王慧中,李炜玉,杨琼,谢德荣..奥沙利铂或伊立替康联合氟尿嘧啶在KRAS突变型的晚期结直肠癌一线化疗中的疗效比较[J].岭南现代临床外科,2016,16(5):553-556,4.基金项目
广东省科技计划项目 （）
